How Are Japan’s New Regenerative Medicine Regulations Playing Out?
This article was originally published in Clinica
Japan formally adopted ground-breaking new and revised legislation governing the regulation of cell and tissue therapies in November 2014 and the feedback on the new framework has been positive.
You may also be interested in...
Emerging Company Profile: With mononuclear stem cell therapy from University of Texas research, new company hopes to address traumatic brain injury by reducing the pro-inflammatory cytokine cascade, which exacerbates the initial injuries in severe TBI.
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.